# CarGurus, Inc.: financial statements, quarterly

CARG · Nasdaq · CIK 1494259 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/carg.md) · [Financials](/companies/carg/financials.md) · [Filings](/companies/carg/filings.md) · [Insiders](/companies/carg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/carg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [219](/filings/0000950170-24-123371.md) | [7.3 d](/filings/0001193125-26-059435.md) | [187](/filings/0001193125-26-059435.md) | [196](/filings/0001193125-26-059435.md) | [205](/filings/0001193125-26-059435.md) | [210](/filings/0001193125-26-059435.md) | [212](/filings/0001193125-26-211983.md) | [222](/filings/0001193125-26-338067.md) | [232](/filings/0001193125-26-059435.md) | [241](/filings/0001193125-26-059435.md) | [244](/filings/0001193125-26-211983.md) | [251](/filings/0001193125-26-338067.md) |
| Cost of revenue | $m | [55.1](/filings/0000950170-24-123371.md) | [(146) d](/filings/0001193125-26-059435.md) | [15.8](/filings/0001193125-26-059435.md) | [15.3](/filings/0001193125-26-059435.md) | [25.1](/filings/0001193125-26-059435.md) | [14.2](/filings/0001193125-26-059435.md) | [14.3](/filings/0001193125-26-059435.md) | [15.7](/filings/0001193125-26-059435.md) | [16.9](/filings/0001193125-26-059435.md) | [18.5](/filings/0001193125-26-059435.md) | [18.9](/filings/0001193125-26-211983.md) | [19.9](/filings/0001193125-26-338067.md) |
| Gross profit | $m | [164](/filings/0000950170-24-123371.md) | [153 d](/filings/0001193125-26-059435.md) | [172](/filings/0001193125-26-059435.md) | [181](/filings/0001193125-26-059435.md) | [179](/filings/0001193125-26-059435.md) | [196](/filings/0001193125-26-059435.md) | [198](/filings/0001193125-26-211983.md) | [206](/filings/0001193125-26-338067.md) | [215](/filings/0001193125-26-059435.md) | [223](/filings/0001193125-26-059435.md) | [225](/filings/0001193125-26-211983.md) | [231](/filings/0001193125-26-338067.md) |
| Research and development | $m | [35.4](/filings/0000950170-24-123371.md) | [27.3 d](/filings/0001193125-26-059435.md) | [35.5](/filings/0000950170-25-066988.md) | [36.6](/filings/0000950170-25-105055.md) | [36.4](/filings/0001193125-25-269604.md) | [30.5 d](/filings/0001193125-26-059435.md) | [35.0](/filings/0001193125-26-211983.md) | [33.7](/filings/0001193125-26-338067.md) | [36.3](/filings/0001193125-25-269604.md) | [31.3 d](/filings/0001193125-26-059435.md) | [37.7](/filings/0001193125-26-211983.md) | [38.1](/filings/0001193125-26-338067.md) |
| Operating income | $m | [23.1](/filings/0000950170-24-123371.md) | [65.4 d](/filings/0001193125-26-059435.md) | [26.3](/filings/0000950170-25-066988.md) | [(93.6)](/filings/0000950170-25-105055.md) | [27.4](/filings/0001193125-25-269604.md) | [197 d](/filings/0001193125-26-059435.md) | [50.7](/filings/0001193125-26-211983.md) | [60.5](/filings/0001193125-26-338067.md) | [54.7](/filings/0001193125-25-269604.md) | [119 d](/filings/0001193125-26-059435.md) | [40.1](/filings/0001193125-26-211983.md) | [63.0](/filings/0001193125-26-338067.md) |
| Income tax | $m | [8.3](/filings/0000950170-24-123371.md) | [23.3 d](/filings/0001193125-26-059435.md) | [8.4](/filings/0000950170-25-066988.md) | [(21.7)](/filings/0000950170-25-105055.md) | [7.5](/filings/0001193125-25-269604.md) | [45.4 d](/filings/0001193125-26-059435.md) | [11.4](/filings/0001193125-26-211983.md) | [14.1](/filings/0001193125-26-338067.md) | [11.9](/filings/0001193125-25-269604.md) | [29.7 d](/filings/0001193125-26-059435.md) | [8.9](/filings/0001193125-26-211983.md) | [14.3](/filings/0001193125-26-338067.md) |
| Net income | $m | [22.3](/filings/0000950170-24-123371.md) | [(17.9) d](/filings/0001193125-26-059435.md) | [21.3](/filings/0001193125-25-269604.md) | [(68.7)](/filings/0001193125-25-269604.md) | [22.5](/filings/0001193125-25-269604.md) | [45.9](/filings/0001193125-26-059435.md) | [39.0](/filings/0001193125-26-338067.md) | [22.3](/filings/0001193125-26-338067.md) | [44.7](/filings/0001193125-25-269604.md) | [49.8](/filings/0001193125-26-059435.md) | [32.2](/filings/0001193125-26-338067.md) | [49.2](/filings/0001193125-26-338067.md) |
| Diluted EPS | $ per share | [0.17](/filings/0000950170-24-123371.md) | not reported | [0.20](/filings/0001193125-26-059435.md) | [(0.65)](/filings/0001193125-26-059435.md) | [0.21](/filings/0001193125-26-059435.md) | [0.43](/filings/0001193125-26-059435.md) | [0.37](/filings/0001193125-26-211983.md) | [0.22](/filings/0001193125-26-338067.md) | [0.45](/filings/0001193125-26-059435.md) | [0.51](/filings/0001193125-26-059435.md) | [0.34](/filings/0001193125-26-211983.md) | [0.54](/filings/0001193125-26-338067.md) |
| Basic EPS | $ per share | [0.20](/filings/0000950170-24-123371.md) | not reported | [0.20](/filings/0001193125-26-059435.md) | [(0.66)](/filings/0001193125-26-059435.md) | [0.22](/filings/0001193125-26-059435.md) | [0.44](/filings/0001193125-26-059435.md) | [0.38](/filings/0001193125-26-211983.md) | [0.23](/filings/0001193125-26-338067.md) | [0.46](/filings/0001193125-26-059435.md) | [0.52](/filings/0001193125-26-059435.md) | [0.34](/filings/0001193125-26-211983.md) | [0.55](/filings/0001193125-26-338067.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [355](/filings/0000950170-23-060248.md) | [291](/filings/0000950170-25-024181.md) | [246](/filings/0000950170-24-056957.md) | [216](/filings/0000950170-24-093956.md) | [247](/filings/0000950170-24-123371.md) | [304](/filings/0001193125-26-059435.md) | [173](/filings/0000950170-25-066988.md) | [231](/filings/0000950170-25-105055.md) | [179](/filings/0001193125-25-269604.md) | [191](/filings/0001193125-26-338067.md) | [72.0](/filings/0001193125-26-211983.md) | [122](/filings/0001193125-26-338067.md) |
| Current assets | $m | [535](/filings/0000950170-23-060248.md) | [391](/filings/0000950170-25-024181.md) | [324](/filings/0000950170-24-056957.md) | [288](/filings/0000950170-24-093956.md) | [327](/filings/0000950170-24-123371.md) | [391](/filings/0001193125-26-059435.md) | [252](/filings/0000950170-25-066988.md) | [309](/filings/0000950170-25-105055.md) | [269](/filings/0001193125-25-269604.md) | [283](/filings/0001193125-26-338067.md) | [162](/filings/0001193125-26-211983.md) | [203](/filings/0001193125-26-338067.md) |
| Total assets | $m | [1,049](/filings/0000950170-23-060248.md) | [919](/filings/0000950170-25-024181.md) | [871](/filings/0000950170-24-056957.md) | [753](/filings/0000950170-24-093956.md) | [778](/filings/0000950170-24-123371.md) | [825](/filings/0001193125-26-059435.md) | [689](/filings/0000950170-25-066988.md) | [726](/filings/0000950170-25-105055.md) | [660](/filings/0001193125-25-269604.md) | [662](/filings/0001193125-26-338067.md) | [520](/filings/0001193125-26-211983.md) | [555](/filings/0001193125-26-338067.md) |
| Current liabilities | $m | [109](/filings/0000950170-23-060248.md) | [115](/filings/0000950170-25-024181.md) | [116](/filings/0000950170-24-056957.md) | [112](/filings/0000950170-24-093956.md) | [111](/filings/0000950170-24-123371.md) | [93.1](/filings/0001193125-26-059435.md) | [94.5](/filings/0000950170-25-066988.md) | [97.2](/filings/0000950170-25-105055.md) | [93.9](/filings/0001193125-25-269604.md) | [101](/filings/0001193125-26-338067.md) | [98.0](/filings/0001193125-26-211983.md) | [110](/filings/0001193125-26-338067.md) |
| Total liabilities | $m | [305](/filings/0000950170-23-060248.md) | [302](/filings/0000950170-25-024181.md) | [302](/filings/0000950170-24-056957.md) | [301](/filings/0000950170-24-093956.md) | [295](/filings/0000950170-24-123371.md) | [283](/filings/0001193125-26-059435.md) | [287](/filings/0000950170-25-066988.md) | [291](/filings/0000950170-25-105055.md) | [285](/filings/0001193125-25-269604.md) | [288](/filings/0001193125-26-338067.md) | [282](/filings/0001193125-26-211983.md) | [291](/filings/0001193125-26-338067.md) |
| Long-term debt | $m | [0.0](/filings/0000950170-23-060248.md) | [0.0](/filings/0000950170-25-024181.md) | [0.0](/filings/0000950170-24-056957.md) | [0.0](/filings/0000950170-24-093956.md) | [0.0](/filings/0000950170-24-123371.md) | [0.0](/filings/0001193125-26-059435.md) | [0.0](/filings/0000950170-25-066988.md) | [0.0](/filings/0000950170-25-105055.md) | [0.0](/filings/0001193125-25-269604.md) | [0.0](/filings/0001193125-26-338067.md) | [0.0](/filings/0001193125-26-211983.md) | [0.0](/filings/0001193125-26-338067.md) |
| Shareholders' equity | $m | [717](/filings/0000950170-24-123371.md) | [617](/filings/0001193125-26-059435.md) | [568](/filings/0001193125-25-269604.md) | [452](/filings/0001193125-25-269604.md) | [483](/filings/0001193125-25-269604.md) | [542](/filings/0001193125-26-338067.md) | [402](/filings/0001193125-26-338067.md) | [435](/filings/0001193125-26-338067.md) | [375](/filings/0001193125-25-269604.md) | [374](/filings/0001193125-26-338067.md) | [237](/filings/0001193125-26-338067.md) | [264](/filings/0001193125-26-338067.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [26.4 d](/filings/0000950170-24-123371.md) | [2.5 d](/filings/0001193125-26-059435.md) | [52.0](/filings/0000950170-25-066988.md) | [71.6 d](/filings/0000950170-25-105055.md) | [56.2 d](/filings/0001193125-25-269604.md) | [75.7 d](/filings/0001193125-26-059435.md) | [67.9](/filings/0001193125-26-211983.md) | [73.1 d](/filings/0001193125-26-338067.md) | [71.2 d](/filings/0001193125-25-269604.md) | [83.1 d](/filings/0001193125-26-059435.md) | [69.8](/filings/0001193125-26-211983.md) | [94.6 d](/filings/0001193125-26-338067.md) |
| Capital expenditure | $m | [4.8 d](/filings/0000950170-24-123371.md) | [15.5 d](/filings/0001193125-26-059435.md) | [28.7](/filings/0000950170-25-066988.md) | [26.0 d](/filings/0000950170-25-105055.md) | [10.3 d](/filings/0001193125-25-269604.md) | [10.2 d](/filings/0001193125-26-059435.md) | [2.2](/filings/0001193125-26-211983.md) | [1.6 d](/filings/0001193125-26-338067.md) | [1.4 d](/filings/0001193125-25-269604.md) | [1.2 d](/filings/0001193125-26-059435.md) | [0.4](/filings/0001193125-26-211983.md) | [0.6 d](/filings/0001193125-26-338067.md) |
| Share repurchases | $m | [16.0 d](/filings/0000950170-24-123371.md) | [101 d](/filings/0001193125-26-059435.md) | [77.4](/filings/0000950170-25-066988.md) | [65.0 d](/filings/0000950170-25-105055.md) | [3.7 d](/filings/0001193125-25-269604.md) | [0.0 d](/filings/0001193125-26-059435.md) | [183](/filings/0001193125-26-211983.md) | [1.8 d](/filings/0001193125-26-338067.md) | [110 d](/filings/0001193125-25-269604.md) | [57.0 d](/filings/0001193125-26-059435.md) | [174](/filings/0001193125-26-211983.md) | [27.7 d](/filings/0001193125-26-338067.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [114](/filings/0000950170-24-093956.md) | [114](/filings/0000950170-24-123371.md) | [109](/filings/0001193125-26-059435.md) | [105](/filings/0001193125-26-059435.md) | [105](/filings/0001193125-26-059435.md) | [106](/filings/0001193125-26-059435.md) | [105](/filings/0001193125-26-211983.md) | [100](/filings/0001193125-26-338067.md) | [99.7](/filings/0001193125-26-059435.md) | [96.8](/filings/0001193125-26-059435.md) | [95.1](/filings/0001193125-26-211983.md) | [91.1](/filings/0001193125-26-338067.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.